Longitudinal MRI study: the effects of azathioprine in MS patients refractory to interferon beta-1b.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 12796549.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
An open-label study was performed to assess the effectiveness of oral azathioprine (AZA) on augmenting the response to interferon beta-1b (IFNbeta-1b) in patients with treatment-refractory relapsing-remitting MS. Six IFNbeta-1b-treated MS patients with continued disease activity were studied on IFNbeta-1b and AZA therapy for a median period of 15 months. A 69% reduction in the number of contrast-enhancing lesions was observed during the combination therapy (p = 0.002).
Medical subject headings
- Azathioprine
- Interferon-beta
- Multiple Sclerosis, Relapsing-Remitting